Pure Biologics (STU:PQB) ROE % Adjusted to Book Value: 0.00% (As of Mar. 2026)


STU:PQB Pure Biologics SA STU:PQB
19 GF Score
Price €0.41
! 2 Warning Signs
View Full Analysis

What is Pure Biologics ROE % Adjusted to Book Value?

Pure Biologics STU:PQB +0.73% 19 ROE % Adjusted to Book Value is 0.00% as of Mar. 2026. GuruFocus rates STU:PQB with a GF Score™ of 19/100. The stock has 2 warning signs investors should review.

Pure Biologics's ROE % for the quarter that ended in Mar. 2026 was 0.00%. Pure Biologics's PB Ratio for the quarter that ended in Mar. 2026 was N/A. Pure Biologics's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2026 was N/A.

Pure Biologics ROE % Adjusted to Book Value Related Terms

Pure Biologics ROE % Adjusted to Book Value Historical Data

* Premium members only.

The historical data trend for Pure Biologics's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pure Biologics ROE % Adjusted to Book Value Chart

Pure Biologics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROE % Adjusted to Book Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only -15.53 -33.44 -17.65 0.00 0.00

Pure Biologics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

STU:PQB vs VRTX, REGN, ALNY: ROE % Adjusted to Book Value Comparison

For the Biotechnology subindustry, Pure Biologics's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Pure Biologics ROE % Adjusted to Book Value vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Pure Biologics's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Pure Biologics's ROE % Adjusted to Book Value falls into.


STU:PQB
19GF Score
Pure Biologics SA STU:PQB
ROE % Adjusted to Book Value is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Pure Biologics ROE % Adjusted to Book Value Calculation

Pure Biologics's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2025 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=0.00% / N/A
=N/A

Pure Biologics's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2026 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=0.00% / N/A
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a ROE % Adjusted to Book Value of 0.00% mean?
Pure Biologics (STU:PQB) has a ROE % Adjusted to Book Value of 0.00% as of Mar. 2026. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Pure Biologics and its competitors.
Is Pure Biologics' ROE % Adjusted to Book Value too high?
Pure Biologics' current ROE % Adjusted to Book Value is 0.00%. Overall, Pure Biologics has a GF Score™ of 19/100, reflecting its overall financial health beyond just this single metric.
How does Pure Biologics' ROE % Adjusted to Book Value compare to VRTX and REGN?
Pure Biologics' ROE % Adjusted to Book Value of 0.00% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Biotechnology company?
A good ROE % Adjusted to Book Value depends on the Biotechnology industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Pure Biologics and its competitors. Pure Biologics's current ROE % Adjusted to Book Value is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pure Biologics stock overvalued right now?
Pure Biologics (STU:PQB) has a current ROE % Adjusted to Book Value of 0.00%. The current ROE % Adjusted to Book Value is 0.00%. Pure Biologics' overall GF Score™ is 19/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For Pure Biologics (STU:PQB), the current ROE % Adjusted to Book Value is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Pure Biologics Business Description

Other Exchanges PUR:Poland
Address ul. Dunska 11, Wroclaw, POL, 54-427
Pure Biologics SA is a Poland based biopharmaceutical company. It invests in the development of new, innovative (non-generic or biosimilar) biological drugs, medical and diagnostic products. It is mainly engaged in the research and development of the biologically active molecule in the drug development process. It specializes in the production and analysis of recombinant proteins and antibodies, contract studies of early product development phases, protein engineering, protein formulation, genomic sequencing, proteomics analysis and bioinformatics. Its projects include cancer immunotherapy, therapy of neurodegenerative diseases, diagnosis of tumors, and other partner projects.
19GF Score

Get the complete analysis for STU:PQB

ROE % Adjusted to Book Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.41
Price